First-in-class transactivator-free, doxycycline-inducible IL-18-engineered CAR-T cells for relapsed/refractory B cell lymphomas.
Autores: Justicia-Lirio P, Tristán-Manzano M, Maldonado-Pérez N, Barbero-Jiménez C, Cortijo-Gutiérrez M, Pavlovic K, Molina-Estevez FJ, Muñoz P, Hinckley-Boned A, Rodriguez-Madoz JR, Prosper F, Griñán-Lison C, Navarro-Marchal SA, Panisello C, Muñoz-Ballester J, González-Sierra PA, Herrera C, Marchal JA, Martín F
08/2024 - Molecular therapy. Nucleic acids